DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms

Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel ME (2022)

Publication Type: Journal article, Review article

Publication year: 2022

Journal

Oncologist Oxford University Press

DOI: 10.1093/oncolo/oyac161

Abstract

This review describes neuroendocrine neoplasms (NEN) classification, incidence, pathogenesis, and current management, focusing on delta-like ligand 3 (DLL3) in NEN progression and prognosis. Therapeutic targeting of DLL3 is addressed, and ongoing studies of DLL3-targeting therapies are summarized.

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

University of Texas MD Anderson Cancer Center

United States (USA) (US) UCSF Helen Diller Family Comprehensive Cancer Center

United States (USA) (US) Dana–Farber Cancer Institute

United States (USA) (US) Louisiana State University

United States (USA) (US) Johns Hopkins University (JHU)

United States (USA) (US) Rizzoli Orthopaedic Institute / Istituto Ortopedico Rizzoli (IRCCS)

Italy (IT) Tohoku University

Japan (JP) Amgen Inc.

United States (USA) (US)

How to cite

APA:

Yao, J., Bergsland, E., Aggarwal, R., Aparicio, A., Beltran, H., Crabtree, J.S.,... Pavel, M.E. (2022). DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. https://doi.org/10.1093/oncolo/oyac161

MLA:

Yao, James, et al. "DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms." Oncologist (2022).

BibTeX: Download